CPIX logo

CPIXCumberland Pharmaceuticals Inc.

$5.80
$0.04
(0.69%)
Today
Closed $5.80
$0.00
(0.00%)
After Hours
Updated: 04:10 PM EDT
EarningsAug 4
Mkt Cap$86.9M
Vol62,169.00
News
all
press releases
Cumberland's Ifetroban Shows Potential to Limit Metastasis
CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.
Zacks
News Placeholder
More News
News Placeholder
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis PR Newswire NASHVILLE, Tenn., June 2, 2026 Positive Results from Phase 2a...
PR Newswire
News Placeholder
Cumberland Expands Global Reach With Vibativ Launch in China
CPIX launches Vibativ in China through SciClone, expanding access to its antibiotic treatment for serious Gram-positive bacterial infections.
Zacks
News Placeholder
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV IN CHINA
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV IN CHINA CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV IN CHINA PR Newswire NASHVILLE, Tenn., May 28, 2026 Commercialization in China through partnership with SciClone PharmaceuticalsExpands access to potentially life-saving...
PR Newswire
News Placeholder
The Zacks Analyst Blog Highlights Alphabet, Apple, Micron Technology, Cumberland Pharmaceuticals and AmeriServ Financial
Alphabet, Apple and Micron lead Zacks analyst reports as AI demand and product cycles drive tech momentum.
Zacks
News Placeholder
Top Analyst Reports for Alphabet, Apple & Micron Technology
Alphabet's AI-driven growth in Search, Cloud and subscriptions is boosting momentum, though spending and legal risks remain in focus.
Zacks
News Placeholder
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
CPIX posts a wider y//y loss in Q1, as it unveils a $100-million Apotex deal and sharpens focus on orphan drug development.
Zacks
News Placeholder
Cumberland Pharmaceuticals (NASDAQ:CPIX) Issues Earnings Results
Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, hitting...
MarketBeat
News Placeholder
Cumberland Pharmaceuticals Q1 Earnings Call Highlights
Cumberland Pharmaceuticals (NASDAQ:CPIX) executives highlighted a planned strategic transaction with Apotex, updates across several marketed brands, and progress in the company's late-stage pipeline...
MarketBeat
News Placeholder
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire NASHVILLE, Tenn., May 5, 2026...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.